Addendum. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43(Suppl. 1):S98–S110

Type 1 Diabetes and COVID-19: Preliminary Findings From a Multicenter Surveillance Study in the U.S.

Section 9, Pharmacologic Approaches to Glycemic Treatment, of the Standards of Medical Care in Diabetes—2020 has been annotated based on a U.S. Food and Drug Administration Drug Safety Communication.The online version of the article (https://doi.org/10.2337/dc20-S009) reflects the changes described below.The following sentence has been added to the “Additional considerations” column for SGLT2 inhibitors in Table 9.1 (p. S101):“FDA safety labeling recommends temporary discontinuation of SGLT2 inhibitors before any scheduled surgery to avoid potential risk for diabetic ketoacidosis.”© 2020 by the American Diabetes Association

Via Source link